Business Wire

Sri Lankan Study Expands Evidence Demonstrating the Benefits of Critical Congenital Heart Disease (CCHD) Screening Using Masimo SET ® Pulse Oximetry

Share

Masimo (NASDAQ: MASI) today announced the results of a prospective study published in the Sri Lanka Journal of Child Health in which researchers in Colombo, Sri Lanka evaluated the efficacy of a pulse oximetry-based critical congenital heart disease (CCHD) newborn screening strategy using Masimo SET® pulse oximetry.1 The authors concluded that pulse oximetry is a “simple, noninvasive, cost-effective, feasible, and reliable test,” and found that it had higher CCHD screening sensitivity than physical exam. Combining the two methods led to detection of all cases of CCHD in the study cohort, and they recommended that, “Pulse oximetry screening as a combined strategy with newborn physical exam should be implemented as a basic routine at discharge for every newborn in maternity units island-wide.” As they note, their work is the first published CCHD study of this nature in Sri Lanka.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210322005184/en/

Masimo SET® Pulse Oximetry (Photo: Business Wire)

Masimo SET® Pulse Oximetry (Photo: Business Wire)

Noting that while “developed countries have abundant research on pulse oximetry screening” for CCHD, “there are few studies in developing countries,” Dr. CR Gunaratne and colleagues sought to study the utility of such a screening strategy in their local setting. From November 2018 to April 2019, researchers assessed the rate of detection of CCHD using Masimo SET® pulse oximetry compared to routine physical exam alone in 5,435 asymptomatic newborns admitted to the post-natal wards at Castle Street Hospital, Colombo. Physical exam was performed at ≥ 24 hours of age “to identify any visible central cyanosis, weak/absent femoral pulses or cardiac murmur” by an experienced medical officer, blinded to pulse oximetry results. Radical-7® Pulse CO-Oximeters® with Masimo SET® pulse oximetry were used to measure pre-ductal and post-ductal oxygen saturation (SpO2) on the right hand and right foot, respectively, as part of a standardized screening algorithm. For newborns with positive results, an echocardiogram was performed within 48 hours to diagnose CCHD.

The researchers found that Masimo SET® pulse oximetry had a CCHD detection rate of 91%, compared to 82% for physical exam. The addition of Masimo SET® pulse oximetry to physical exam screening led to the detection of 2 cases missed by physical exam alone, with a combined detection rate of 100%. The positive predictive value and positive likelihood ratio were both higher for SET® pulse oximetry compared to physical exam (71.4% vs. 8.6% and 1232.7 vs. 46.2, p = 0.0001). The researchers also found that the false positive rate was “substantially” lower for SET® pulse oximetry compared to physical exam (0.07% vs. 1.76%, p = 0.0001).

The researchers concluded, “Prevalence of CCHD in our study was 2.02 per 1000 live births. Using a pulse oximetry strategy as an adjunct to routine physical exam can substantially reduce the diagnostic gap in CCHD as [a] combined approach has an additive effect resulting in more efficient screening.”

Since its introduction in 1995, Masimo Measure-through Motion and Low Perfusion™ Signal Extraction Technology® (SET®) has been shown in more than 100 independent and objective studies to outperform other pulse oximetry technologies, providing clinicians with increased sensitivity and specificity to help them make critical patient care decisions.2 To date, nine other published CCHD screening studies, all with positive conclusions and representing over 300,000 infants, have used Masimo SET®,3-11 which includes the largest CCHD study to date, of 122,738 newborns.5 All of the CCHD studies with Masimo SET® pulse oximetry have shown improved screening sensitivity with the use of Masimo SET® alongside clinical assessment when compared to routine physical exam alone. Results from CCHD studies using other pulse oximetry technologies have shown that other technologies do not offer the same performance as Masimo SET® during CCHD screening.12-14

With its ability to accurately measure through motion and low perfusion, alongside its performance in outcome studies, SET® stands out as the choice of pulse oximetry technology for clinicians and policy makers hoping to implement newborn-related screening processes—and has indeed been used in the establishment of screening guidelines used around the world.15

@Masimo | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.2 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,16 improve CCHD screening in newborns,3 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.17-20 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,21 and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2020-21 U.S. News and World Report Best Hospitals Honor Roll.22 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView :60™, and Masimo SafetyNet™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

  1. Gunaratne CR, Hewage I, Fonseka A, Thennakoon S. Comparison of pulse oximetry screening versus routine clinical examination in detecting critical congenital heart disease in newborns. Sri Lanka J Child Health, 2021; 50(1): 04-11. DOI: http://dx.doi.org/10.4038/sljch.v50i1.9393.
  2. Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
  3. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
  4. Slitine N, et al. Pulse Oximetry and Congenital Heart Disease Screening: Results of the First Pilot Study in Morocco. Int J Neonatal Screen 6(53). 30 June 2020.
  5. Zhao et al. Pulse oximetry with clinical assessment to screen for congenital heart disease in neonates in China: a prospective study. Lancet. 2014 Aug 30;384(9945):747-54.
  6. Ewer AK et al. Pulse Oximetry Screening for Congenital Heart Defects in Newborn Infants (Pulseox): A Test Accuracy Study. Lancet. 2011 Aug 27;378(9793):785-94.
  7. de-Wahl Granelli A et al. Noninvasive Peripheral Perfusion Index as a Possible Tool for Screening for Critical Left Heart Obstruction. Acta Paediatr 2007; 96(10): 1455-9.
  8. Meberg A et al. First Day of Life Pulse Oximetry Screening to Detect Congenital Heart Defects. J Pediatr 2008; 152:761-5.
  9. Schena F et al. Perfusion Index and Pulse Oximetry Screening for Congenital Heart Defects. J Pediatr. 2017 Apr;183:74-79.
  10. Hamilçıkan S, Can E. Critical Congenital Heart Disease Screening With a Pulse Oximetry in Neonates. J Perinat Med. 2018 Feb 23;46(2):203-207.
  11. Jawin V et al. Beyond Critical Congenital Heart Disease: Newborn Screening Using Pulse Oximetry for Neonatal Sepsis and Respiratory Diseases in a Middle-Income Country. PLoS One. 2015; 10(9): e0137580.
  12. Tekleab AM, Sewnet YC. Role of pulse oximetry in detecting critical congenital heart disease among newborns delivered at a high altitude setting in Ethiopia. Pediatric Health Med Ther. 2019;10:83-88. https://doi.org/10.2147/PHMT.S217987.
  13. Narayen IC et al. Accuracy of Pulse Oximetry Screening for Critical Congenital Heart Defects After Home Birth and Early Postnatal Discharge. J Pediatr. 2018;197:29-35.
  14. Oakley JL et al. Effectiveness of Pulse-Oximetry in Addition to Routine Neonatal Examination in Detection of Congenital Heart Disease in Asymptomatic Newborns. J Matern Fetal Neonatal Med. 2015;28(14):1736-9.
  15. Kemper et al. Strategies for implementing screening for critical congenital heart disease. Pediatrics. 2011 Nov;128(5):e1259-67. doi: 10.1542/peds.2011-1317.
  16. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
  17. Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
  18. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
  19. McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
  20. McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
  21. Estimate: Masimo data on file.
  22. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of SET®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including SET®, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Contact information

Masimo
Evan Lamb
949-396-3376
elamb@masimo.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BIO KOREA 2021 International Convention Is Ready - Showing What Makes Korea’s Bio-health Market at Record High20.4.2021 14:00:00 CEST | Press release

The 16th edition of BIO KOREA, the reference B2B event for global biotech and health industry professionals interested in opportunities in the Asian region, will be held online from 9th to 21st June 2021 with an onsite show at COEX in Seoul from 9th to 11th June. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005089/en/ In the global market, the bio-health industry is notching an annual average growth rate of 4 percent, higher than the shipbuilding and auto-making industry at 2.9 percent and at 1.5 percent, respectively. Especially, the Korean bio-health industry shows remarkable growth – its bio-health industry set a new milestone in outbound shipments with a 50 percent jump last year, led by robust demand for COVID-19 test kits and biosimilar products. With the record high export figures, the bio-health sector joins the ranks of the mainstay export industry for the first time in its history. The game-changers of the

Woolworths Group Selects One Door to Improve the Store Team Experience20.4.2021 14:00:00 CEST | Press release

One Door, Inc., the leading provider of cloud-based visual merchandising software, today announced a new multi-year agreement with the Woolworths Group. Woolworths will implement One Door’s Merchandising Cloud platform across its supermarkets to simplify and streamline work for its in-store merchandising teams. “We are thrilled to partner with Woolworths to have a positive impact on the lives of their customers and team,” said Tom Erskine, CEO of One Door. “Woolworths is a proven retail innovator and we both believe we are only just beginning to jointly understand how these technologies can ultimately improve the work experience for store teams and improve the overall customer experience.” “We’re pleased to partner with One Door to roll out Merchandising Cloud for the benefit of our teams and customers,” said Doug Frank, Woolworths General Manager Group Data & Analytics. “One Door allows us to simplify a critical and time intensive task - making life easier for in-store merchandisers a

Munich Re’s Consulting Unit Boosts Its Pricing Capabilities With Akur8 in Global Cooperation20.4.2021 14:00:00 CEST | Press release

Akur8 is delighted to announce their global cooperation agreement with Munich Re to boost Munich Re’s pricing capabilities for their Global Consulting Unit1. With this agreement, Munich Re will have access to a new state-of-the-art rate modelling solution and Akur8 will reinforce its footprint by partnering with one of the world’s leading providers of insurance, reinsurance and insurance-related risk solutions. This non-exclusive cooperation is global, with users in multiple Munich Re operating geographies. All Munich Re entities and clients can benefit from the joint approach and tap into this solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005018/en/ Specifically developed for insurance, Akur8’s solution enhances insurers’ pricing processes by automating risk and demand modelling, using transparent Artificial Intelligence proprietary technology. The core benefits for insurers include a reduction in modelling

Globality Recognized as HFS Hot Vendor by HFS Research20.4.2021 14:00:00 CEST | Press release

Globality, the technology company behind the leading AI-powered digital Platform for sourcing complex, enterprise services, has been recognized as an HFS Hot Vendor by HFS Research, the leading analyst advisory authority covering global IT services, emerging technologies and business operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005687/en/ (Graphic: Business Wire) In the HFS Hot Vendor Report Q1 2021, HFS commends Globality for having “an innovative solution for smart self-sourcing utilizing the combination of automation, AI, and analytics,” while noting that “early mover advantage in the self-service procurement space provides a competitive advantage.” As the report highlights: “With Globality’s sourcing platform, enterprises can embark on intelligent self-service procurement that helps them understand the risks of what they buy, effectively collaborating with stakeholders during the sourcing process, ide

Anari AI Raises $2M to Rebuild the AI Hardware Industry Through Personalized Cloud Chips20.4.2021 13:59:00 CEST | Press release

Anari AI, an AI chip factory in the cloud, today announced it has raised $2 million in seed funding led by Earlybird, with participation from Acequia Capital, Serbian Entrepreneurs, and Eric Ries, author and founder of The Lean Startup. The new funding will be used to continue developing the platform and bring it to market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005700/en/ Anari AI: Hardware as code (Photo: Business Wire) Anari’s platform makes it possible to design personalized AI chips in the cloud with just one click. With this approach, companies are able to build and deploy AI solutions in weeks instead of 12-18 months, and at a fraction of the cost of traditional hardware development. “AI continues to be growing in size and complexity, and this rate of growth is outpacing standard CPU and GPU performance gains,” said Roland Manger, co-founder and Partner at Earlybird. “Dedicated designs or flexible archit

New gPROMS Process – Process Modelling and Optimization for the Digital World20.4.2021 13:47:00 CEST | Press release

Process Systems Enterprise (PSE), a Siemens business, today released its rebranded gPROMS Process advanced process modelling environment. Formerly known as gPROMS ProcessBuilder, gPROMS Process 2.0 is the first major release since PSE was acquired by Siemens. Eckard Eberle, CEO of Siemens Digital Industries Process Automation division, says “the significantly enhanced capabilities and functionality you see in this release reflect the substantial investment Siemens is making into product development within PSE to provide the process industries with a new generation of digital tools.” Costas Pantelides, PSE CEO and architect of the gPROMS platform, says “The name change signifies a break with the past. Until now, ProcessBuilder has been an environment for sophisticated users who are typically running high-value, complex optimizations. This is the first release in a major, multi-year development programme that will bring the cutting-edge capabilities of the gPROMS platform to users across

Velodyne Lidar Signs Multi-Year Sales Agreement with Gatik20.4.2021 12:48:00 CEST | Press release

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced a multi-year sales agreement with Gatik, the industry leader in automating on-road transportation networks for B2B middle mile logistics. Gatik uses Velodyne’s lidar sensors as a key part of a fully redundant sensor suite to deliver goods safely and efficiently between micro-fulfilment centers, dark stores and retail locations – a logistics flow known as the middle mile. Gatik fulfills revenue-generating autonomous orders daily for multiple Fortune 500 customers in the US and Canada, including Walmart, reducing customer costs and keeping delivery times short. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005317/en/ Velodyne Lidar announced a multi-year sales agreement with Gatik, industry leader in automating on-road transportation networks for B2B middle mile logistics. Gatik uses Velodyne’s lidar sensors to support short-haul logistics with precise, reliable